Publications by authors named "Sebastien Lorenzo"

Claim this Profile
D
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.
Francois Pierre Combes, Sherwin K B Sy, Ying Fei Li, Sebastien Lorenzo, Kohinoor Dasgupta

Clin Pharmacokinet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study.
Thomas Marbury, Mona El-Hashimy, Lars Blumenstein, Franck Letellier, Tirtha Sengupta, Sebastien Lorenzo

J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
François Pierre Combes, Ying Fei Li, Matthias Hoch, Sebastien Lorenzo, Yu-Yun Ho

Clin Pharmacol Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Ying Fei Li, Francois Pierre Combes, Matthias Hoch, Sebastien Lorenzo, Sherwin K B Sy

Clin Pharmacokinet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Ying Fei Li, Francois Pierre Combes, Matthias Hoch, Sebastien Lorenzo, Sherwin K B Sy

Clin Pharmacokinet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Monika Gajewska, Lars Blumenstein, Alexandros Kourentas, Martin Mueller-Zsigmondy, Sebastien Lorenzo

AAPS J· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
Denes Csonka, Katharine Hazell, Edward Waldron, Sebastien Lorenzo, Vincent Duval

J Clin Pharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
Catherine Dutreix, Sebastien Lorenzo, Yanfeng Wang

Eur J Clin Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Catherine Dutreix, Florence Munarini, Sebastien Lorenzo, Johannes Roesel, Yanfeng Wang

Cancer Chemother Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers.
Adam del Corral, Catherine Dutreix, Alice Huntsman-Labed, Sebastien Lorenzo, Joel Morganroth

Cancer Chemother Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis